Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Neurological presentations of the antiphospholipid syndrome: three illustrative cases

Neurological presentations of the antiphospholipid syndrome: three illustrative cases The antiphospholipid syndrome (APS) is defined by the association of high titers of antiphospholipid antibodies (aPLs) with thrombotic events and/or obstetrical problems. APS can be isolated or associated with immune system diseases. Several central nervous system (CNS) manifestations have been reported in APS, but are still not included in the international diagnostic criteria. We present here three cases of APS revealed by CNS manifestations. The first patient had a primary APS with stroke, dementia, epilepsy and the “so-called” Liebman–Sacks disease, a subacute thrombotic non-bacterial valvulopathy. The second one developed a primary APS with a Sneddon syndrome, while the third case is a neurolupus-associated APS with subacute encephalopathy, chorea, stroke, and epilepsy. The pathogenesis of the APS is related to both prothrombotic and immunologic effects of the aPLs. Long-term anticoagulation by low-weight heparin or warfarin is currently recommended in APS. We propose to search the presence of aPLs in any case of young adults’ stroke, unexplained dementia, and acquired chorea. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Acta Neurologica Belgica Springer Journals

Neurological presentations of the antiphospholipid syndrome: three illustrative cases

Download PDF
7 pages

Loading next page...
 
/lp/springer-journals/neurological-presentations-of-the-antiphospholipid-syndrome-three-jUw0C0QrIp
Publisher
Springer Journals
Copyright
Copyright © 2014 by Belgian Neurological Society
Subject
Biomedicine; Neurosciences; Neurology; Neuroradiology; Medicine/Public Health, general
ISSN
0300-9009
eISSN
2240-2993
DOI
10.1007/s13760-013-0275-6
pmid
24464766
Publisher site
See Article on Publisher Site

Abstract

The antiphospholipid syndrome (APS) is defined by the association of high titers of antiphospholipid antibodies (aPLs) with thrombotic events and/or obstetrical problems. APS can be isolated or associated with immune system diseases. Several central nervous system (CNS) manifestations have been reported in APS, but are still not included in the international diagnostic criteria. We present here three cases of APS revealed by CNS manifestations. The first patient had a primary APS with stroke, dementia, epilepsy and the “so-called” Liebman–Sacks disease, a subacute thrombotic non-bacterial valvulopathy. The second one developed a primary APS with a Sneddon syndrome, while the third case is a neurolupus-associated APS with subacute encephalopathy, chorea, stroke, and epilepsy. The pathogenesis of the APS is related to both prothrombotic and immunologic effects of the aPLs. Long-term anticoagulation by low-weight heparin or warfarin is currently recommended in APS. We propose to search the presence of aPLs in any case of young adults’ stroke, unexplained dementia, and acquired chorea.

Journal

Acta Neurologica Belgica – Springer Journals

Published: Jan 25, 2014

References

  • The anticardiolipin syndrome
    Hughes, G; Harris, NN; Gharavi, AE
  • International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
    Miyakis, S; Lockshin, MD; Atsumi, T
  • Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case–control study
    Urbanus, RT; Siegerink, B; Roest, M
  • Antiphospholipid antibodies and the central nervous system
    Bodiguel, E
  • Antiphospholipid syndrome and homozygous factor V Leiden mutation in a young patient with Libeman–sacks endocarditis and stroke
    Morrissette, N; Gorman, T
  • The pathogenesis of the antiphospholipid syndrome
    Giannakopoulos, B; Krilis, SA
  • Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the “CAPS Registry”
    Cervera, R; Bucciarelli, S; Plasín, MA
  • Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid syndrome
    Asherson, RA; Khamashta, MA; Gil, A
  • Neurological disease associated with antiphospholipid syndrome
    Briley, DP; Coull, BM; Goodnight, SH
  • Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome
    Krause, I; Lev, S; Fraser, A
  • Antiphospholipid syndrome in young adults with stroke
    Brey, R
  • Antiphospholipid syndrome and the brain in pediatric and adult patients
    Muscal, E; Brey, RL
  • Prognosis of cerebral vein and dural sinus thrombosis: results of the international study on cerebral vein and dural sinus thrombosis (ISCVT)
    Ferro, JM; Canhão, P; Stam, J
  • Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients
    Cervera, R; Piette, JC; Font, J
  • Dementia associated with the antiphospholipid syndrome: clinical and radiological characteristics of 30 patients
    Gomez-Puerta, JA; Cervera, R; Calvo, LM
  • Clinical, neurovascular and neuropathological features in Sneddon’s syndrome
    Marinho, JL; Piovesan, EJ; Pereira Leite Neto, M
  • Syndrome démentiel révélant un syndrome de Sneddon
    Montané de la Roque, P; Michard, JF; Pinganaud-Shrestha, C
  • Livedo racemosa: a striking dermatological sign for the antiphospholipid syndrome
    Uthman, IW; Khamashta, MA
  • Sneddon’s syndrome: 15 cases with cerebral angiography
    Maamar, M; Rahmani, M; Aidi, S
  • Sneddon’s syndrome: case report and review of its relationship with antiphospholipid syndrome
    Dutra, L; Braga-Neto, P; Pedroso, JL
  • Le syndrome de Sneddon
    Benaye, J; Hsaini, Y; Zoobo, T
  • Sneddon’s syndrome. Diagnostic by skin biopsy and RMI in 17 patients
    Stockhammer, G; Stephan, R; Felber, R
  • Sneddon syndrome with or without antiphospholipid antibodies. A comparative study in 46 patients
    Francès, C; Papo, T; Wechsler, B
  • Neuropsychiatric syndromes in lupus: prevalence using standardized definitions
    Brey, RL; Holliday, SL; Saklad, AR
  • CNS lupus: a study of 41 patients
    Joseph, FG; Lammie, GA; Scolding, NJ
  • Clinical, laboratory and neuroimage findings in juvenile systemic lupus erythematosus presenting involvement of the nervous system
    Spinosa, MJ; Bandeira, M; Liberalesso, PB
  • Chorea in systemic lupus erythematosus and “lupus-like” disease: association with antiphospholipid antibodies
    Asherson, RA; Derksen, RH; Harris, EN
  • Chorea in systemic lupus erythematosus
    Baizabal-Carvallo, J; Alonso-Juarez, M; Koslowski, M
  • Chorea in the antiphospholipid syndrome. Clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and the recent literature
    Cervera, R; Asherson, RA; Font, J
  • Lupus anticoagulant and chorea
    Fuente-Fernández, R
  • A follow-up study of antiphospholipid antibodies and associated neuropsychiatric manifestations in 137 children with systemic lupus erythematosus
    Avcin, T; Benseler, SM; Tyrrell, PN
  • Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals
    Erkan, D; Harrison, MJ; Levy, R
  • Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients
    Cervera, R; Khamashta, MA; Shoenfeld, Y
  • The pathogenesis of the antiphospholipid syndrome
    Giannakopoulos, B; Krilis, SA
  • Management of antiphospholipid antibody syndrome: a systematic review
    Lim, W; Crowther, MA; Eikelboom, JW
  • A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome
    Crowther, MA; Ginsberg, JS; Julian, J
  • A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)
    Finazzi, G; Marchioli, R; Brancaccio, V
  • Management of antiphospholipid syndrome
    Saadoun, D; Piette, J-C; Wahl, D
  • Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients
    Asherson, RA; Cervera, R; Piette, JC
  • Catastrophic antiphospholipid syndrome: where do we stand?
    Erkan, D; Cervera, R; Asherson, RA
  • Antiphospholipid syndrome in patients with systemic lupus erythematosus treated by autologous hematopoietic stem cell transplantation
    Statkute, L; Traynor, A; Oyama, Y
  • A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome
    Erkan, D; Vega, J; Ramón, G
  • Use of new oral anticoagulants in antiphospholipid syndrome
    Arachchillage, DJ; Cohen, H
  • Antiphospholipid syndrome: from pathogenesis to novel immunomodulatory therapies
    Comarmond, C; Cacoub, P
  • Potential use of statins in the treatment of antiphospholipid syndrome
    Lopez-Pedrera, C; Ruiz-Limon, P; Aguirre, MA